SOURCE: Equity Markets Inc

July 20, 2011 09:00 ET

Research Report on Gilead Sciences, Inc. and Bristol-Myers Squibb Company - New Innovations Facilitate Recovery

MACAU--(Marketwire - Jul 20, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting Gilead Sciences, Inc. (NASDAQ: GILD) and Bristol-Myers Squibb Company (NYSE: BMY). Full content and research is available at www.EquityMarketsInc.com/research.php.

This sector demonstrates renewed investor interest as new and lucrative therapies come to market. The FDA approved the first new drug in 50 years to treat the auto-immune disorder lupus in March 2011, and we expect approval of new treatments for the Hepatitis C virus around mid-year. The 2010 health care reform act authorized by the FDA, will establish a regulatory pathway for approving "biosimilar" drugs, which in turn will increase production and shorten FDA approval times. Pharmaceuticals should remain one of the widest-margin industries, with prospects enhanced by demographic growth in the elderly and new drugs stemming from discoveries in genomics and biotechnology.

Equity Markets has reviewed Gilead Sciences, Inc. as a biopharmaceutical company focused on the development and commercialization of human therapeutics for life threatening diseases. The Company has operations in North America, Europe and Asia Pacific. The Company's products include Truvada, Atripla, Viread, Emtriva, Hepsera, AmBisome, Letairis, Ranexa, Vistide and Cayston. Its products are marketed through its commercial teams and/or in conjunction with third-party distributors and corporate partners. The full research report on Gilead Sciences, Inc. (NASDAQ: GILD) is available here: www.EquityMarketsInc.com/researchfile4634.php.

Equity Markets is covering Bristol-Myers Squibb Company as it is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical products on a global basis. The Company's products are sold worldwide, primarily to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in eight foreign countries. The Company's pharmaceutical products include chemically-synthesized drugs, or small molecules, and an increasing portion of products produced from biological processes called biologics. The full research report on Bristol-Myers Squibb Company (NYSE: BMY) is available here: www.EquityMarketsInc.com/researchfile4891.php.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information